GlassScriptPhysician profile
Tuna Ustunkaya
NPI 1366901647
$1,640.97
in general payments reported to CMS, 2019-2025
17 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.36 |
| Education | $144.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $265.81 | 2025 | |
| Amgen INC. | $252.91 | 2025 | Repatha |
| Agepha Pharma Fz LLC | $159.46 | 2025 | Lodoco |
| Abbott Laboratories | $144.61 | 2025 | Ensite |
| Stryker Corporation | $143.59 | 2025 | Flowtriever |
| Bridgebio Pharma, INC. | $125.87 | 2025 | Attruby |
| Chiesi USA, INC. | $100.44 | 2025 | Kengreal |
| Astrazeneca Pharmaceuticals LP | $86.25 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.58 | 2025 | Lifevest |
| Medtronic, INC. | $57.24 | 2025 | Aurora Ev-Icd Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $57.01 | 2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $43.38 | 2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $34.61 | 2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $32.52 | 2025 | |
| Boston Scientific Corporation | $23.70 | 2025 | Watchman Flx |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $21.42 | 2025 | |
| Cardiva Medical, INC. | $19.57 | 2025 | Optowire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuna Ustunkaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.